Latest News of YMAB
Y-mAbs Therapeutics Inc (YMAB) Q3 2024 Earnings Call Highlights: Navigating Revenue Challenges ...
By Yahoo! Finance |
1 week ago
The key criteria for dose selection in the GD2 SADA study were based on preclinical PK data, aiming for optimal dosing near the NOAEL. The CFO is confident in hitting Q4 revenue guidance of $87 to $95...
While shareholders of Y-mAbs Therapeutics (NASDAQ:YMAB) are in the black over 1 year, those who bought a week ago aren't so fortunate
By Yahoo! Finance |
1 month ago
Investing in stocks carries risks, but finding a high-quality company like Y-mAbs Therapeutics (YMAB) can yield significant returns. Despite recent fluctuations, its long-term performance and revenue ...
Y-mAbs Therapeutics, Inc. (YMAB): One of Caligan Partners' Top Holdings Now?
By Yahoo! Finance |
3 months ago
Caligan Partners, a significant specialty hedge fund, focuses on healthcare investments in the US. They engage in activist strategies, pushing for strategic changes in companies to enhance shareholder...
-
We're Not Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn
By Yahoo! Finance | 4 months agoDespite losing money, shareholders can profit if they buy a good business at the right price. Y-mAbs Therapeutics has a reassuringly long cash runway of about 4.3 years, showing progress with reduced ...